Changmao Biochemical Engineering Company Limited (0954.HK)
HKD 0.41
(1.25%)
HKD 0.41
(1.25%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 590.9 Million CNY | 38.11% |
| 2022 | 427.86 Million CNY | 65.2% |
| 2021 | 258.98 Million CNY | 31.19% |
| 2020 | 197.41 Million CNY | 161.74% |
| 2019 | 75.42 Million CNY | -25.43% |
| 2018 | 101.15 Million CNY | -33.2% |
| 2017 | 151.42 Million CNY | 73.05% |
| 2016 | 87.5 Million CNY | -45.61% |
| 2015 | 160.89 Million CNY | 2.82% |
| 2014 | 156.48 Million CNY | -1.1% |
| 2013 | 158.22 Million CNY | -20.23% |
| 2012 | 198.34 Million CNY | -16.23% |
| 2011 | 236.77 Million CNY | 6.29% |
| 2010 | 222.76 Million CNY | 18.64% |
| 2009 | 187.76 Million CNY | -0.69% |
| 2008 | 189.08 Million CNY | -12.98% |
| 2007 | 217.28 Million CNY | 18.34% |
| 2006 | 183.61 Million CNY | 59.61% |
| 2005 | 115.03 Million CNY | 33.93% |
| 2004 | 85.89 Million CNY | 12.89% |
| 2003 | 76.08 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 635.7 Million CNY | 0.0% |
| 2024 Q1 | 635.7 Million CNY | 7.58% |
| 2023 Q3 | 590.9 Million CNY | 10.5% |
| 2023 FY | 590.9 Million CNY | 38.11% |
| 2023 Q4 | 590.9 Million CNY | 0.0% |
| 2023 Q1 | 534.76 Million CNY | 24.99% |
| 2023 Q2 | 534.76 Million CNY | 0.0% |
| 2022 Q1 | 411.22 Million CNY | 58.78% |
| 2022 Q2 | 411.22 Million CNY | 0.0% |
| 2022 Q3 | 427.86 Million CNY | 4.04% |
| 2022 FY | 427.86 Million CNY | 65.2% |
| 2022 Q4 | 427.86 Million CNY | 0.0% |
| 2021 Q2 | 249.7 Million CNY | 0.39% |
| 2021 FY | 258.98 Million CNY | 31.19% |
| 2021 Q1 | 248.74 Million CNY | 26.0% |
| 2021 Q3 | 258.98 Million CNY | 3.72% |
| 2021 Q4 | 258.98 Million CNY | 0.0% |
| 2020 Q2 | 108.49 Million CNY | 1.43% |
| 2020 Q3 | 196.33 Million CNY | 80.96% |
| 2020 Q4 | 197.41 Million CNY | 0.55% |
| 2020 Q1 | 106.96 Million CNY | 41.82% |
| 2020 FY | 197.41 Million CNY | 161.74% |
| 2019 Q3 | 75.42 Million CNY | -16.5% |
| 2019 Q2 | 90.32 Million CNY | 2.53% |
| 2019 Q4 | 75.42 Million CNY | 0.0% |
| 2019 FY | 75.42 Million CNY | -25.43% |
| 2019 Q1 | 88.1 Million CNY | -12.9% |
| 2018 Q4 | 101.15 Million CNY | 2.47% |
| 2018 Q2 | 107.87 Million CNY | 2.51% |
| 2018 FY | 101.15 Million CNY | -33.2% |
| 2018 Q1 | 105.23 Million CNY | -30.5% |
| 2018 Q3 | 98.71 Million CNY | -8.5% |
| 2017 Q3 | 148.51 Million CNY | 33.99% |
| 2017 Q4 | 151.42 Million CNY | 1.96% |
| 2017 FY | 151.42 Million CNY | 73.05% |
| 2017 Q1 | 107.8 Million CNY | 23.2% |
| 2017 Q2 | 110.84 Million CNY | 2.82% |
| 2016 Q3 | 85.04 Million CNY | -22.51% |
| 2016 FY | 87.5 Million CNY | -45.61% |
| 2016 Q4 | 87.5 Million CNY | 2.89% |
| 2016 Q2 | 109.74 Million CNY | 0.28% |
| 2016 Q1 | 109.44 Million CNY | -31.98% |
| 2015 Q4 | 160.89 Million CNY | 0.16% |
| 2015 Q1 | 126.06 Million CNY | -19.44% |
| 2015 FY | 160.89 Million CNY | 2.82% |
| 2015 Q2 | 126.39 Million CNY | 0.26% |
| 2015 Q3 | 160.63 Million CNY | 27.09% |
| 2014 Q4 | 156.48 Million CNY | 0.22% |
| 2014 Q3 | 156.13 Million CNY | -28.51% |
| 2014 Q2 | 218.4 Million CNY | 0.21% |
| 2014 Q1 | 217.95 Million CNY | 38.16% |
| 2014 FY | 156.48 Million CNY | -1.1% |
| 2013 Q2 | 210.69 Million CNY | 0.0% |
| 2013 Q3 | 157.75 Million CNY | -25.13% |
| 2013 Q4 | 157.75 Million CNY | 0.0% |
| 2013 FY | 158.22 Million CNY | -20.23% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 FY | 198.34 Million CNY | -16.23% |
| 2012 Q3 | - CNY | -100.0% |
| 2012 Q4 | 198.34 Million CNY | 0.0% |
| 2012 Q2 | 247.82 Million CNY | 0.0% |
| 2011 FY | 236.77 Million CNY | 6.29% |
| 2011 Q2 | 255.5 Million CNY | 0.0% |
| 2011 Q4 | 236.77 Million CNY | 0.0% |
| 2010 Q2 | 230.05 Million CNY | 0.0% |
| 2010 FY | 222.76 Million CNY | 18.64% |
| 2010 Q4 | 222.76 Million CNY | 0.0% |
| 2009 FY | 187.76 Million CNY | -0.69% |
| 2008 FY | 189.08 Million CNY | -12.98% |
| 2007 FY | 217.28 Million CNY | 18.34% |
| 2006 FY | 183.61 Million CNY | 59.61% |
| 2005 FY | 115.03 Million CNY | 33.93% |
| 2004 FY | 85.89 Million CNY | 12.89% |
| 2003 FY | 76.08 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Wai Chun Bio-Technology Limited | 229.69 Million HKD | -157.261% |
| Lee & Man Chemical Company Limited | 1.22 Billion HKD | 51.928% |